NY Financial Regulator Files Insurance Fraud Charges Against Opioid Manufacturers
New York’s Department of Financial Services (DFS) has filed insurance fraud charges against opioid manufacturers Teva Pharmaceuticals and Allergan Plc.
According to a statement from Governor Andrew Cuomo, the DFS alleged in its filing that both Teva and Allergan took part in fraudulent marketing and promotional campaigns – campaigns which misrepresented the safety and effectiveness of opioid drugs.
Reuters reached out to both Teva and Allergan for comment, but neither were able to immediately respond.
Read more: Healthcare fraud tops $2 billion for tenth year in a row
In 2019, opioid manufacturer Insys Therapeutics paid $195 million to settle civil allegations that it gave kickbacks to physicians and nurses, bribing them to prescribe the company’s own drug Subsys for patients.
People Power: Building The Future Of Insurance One Career At A Time
The insurance industry is at a pivotal point. As emerging technologies reshape underwriting, claims processing, and cust... Read more
Private Equity's Great Divide: Is The Future Insurance-Funded Or Fee-Driven?
A fundamental shift is taking place at the top of the private equity industry. While firms like Blackstone remain commit... Read more
Japan's Next Battleground: The Insurance Sector Under Activist Pressure
Farallon’s push at T&D Holdings marks a shift in focus for activist capital targeting Japan’s untapped insurance... Read more
Cover And Conflict: Tensions Rise Between Insurers And Litigation Funders
Burford’s clash with Chubb signals a deeper rift in the legal-financial ecosystem A high-profile dispute between li... Read more
Underwater And Uninsured: How Climate Risk Is Reshaping The US Mortgage Market
As climate change intensifies, its effects are no longer confined to coastlines or news reports on extreme weather. In t... Read more
When The Raters Get Rated: What The Fitch–Kroll Feud Says About Oversight And Accountability
In a rare and unusually public confrontation between two of America’s credit rating agencies, a recent feud between Fi... Read more